Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

• Verfasst von: Zimmer, Lisa [VerfasserIn]
• Verfasst von: Utikal, Jochen [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Titel: Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
• Verf.angabe: Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu, Lisa A. Kottschade, Andrea Forschner, Ralf Gutzmer, Max Schlaak, Lucie Heinzerling, Angela M. Krackhardt, Carmen Loquai, Svetomir N. Markovic, Richard W. Joseph, Kelly Markey, Jochen S. Utikal, Carsten Weishaupt, Simone M. Goldinger, Vernon K. Sondak, Jonathan S. Zager, Dirk Schadendorf, Nikhil I. Khushalani
• E-Jahr: 2017
• Jahr: 17 February 2017
• Umfang: 9 S.
• Fussnoten: Gesehen am 17.08.2018
• Titel Quelle: Enthalten in: European journal of cancer
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1992
• Jahr Quelle: 2017
• Band/Heft Quelle: 75(2017), Seite 47-55
• ISSN Quelle: 1879-0852
• DOI: doi:10.1016/j.ejca.2017.01.009
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Anti-PD-1
• Sach-SW: Disease progression
• Sach-SW: Efficacy
• Sach-SW: Ipilimumab
• Sach-SW: Ipilimumab and nivolumab
• Sach-SW: Melanoma
• Sach-SW: Nivolumab
• Sach-SW: Pembrolizumab
• Sach-SW: Treatment failure
• K10plus-PPN: 1580170293

Abstract

Background: The anti-programmed cell death-1 (PD-1) inhibitors pembrolizumab and nivolumab alone or in combination with ipilimumab have shown improved objective response rates and progression-free survival compared to ipilimumab only in advanced melanoma patients. Anti-PD-1 therapy demonstrated nearly equal clinical efficacy in patients who had progressed after ipilimumab or were treatment-naïve. However, only limited evidence exists regarding the efficacy of ipilimumab alone or in combination with nivolumab after treatment failure to anti-PD-therapy. Patients and methods: A multicenter retrospective study in advanced melanoma patients who were treated with nivolumab (1 or 3 mg/kg) and ipilimumab (1 mg or 3 mg/kg) or ipilimumab (3 mg/kg) alone after treatment failure to anti-PD-1 therapy was performed. Patient, tumour, pre- and post-treatment characteristics were analysed. Results: In total, 47 patients were treated with ipilimumab (ipi-group) and 37 patients with ipilimumab and nivolumab (combination-group) after treatment failure to anti-PD-1 therapy. Overall response rates for the ipi- and the combination-group were 16% and 21%, respectively. Disease control rate was 42% for the ipi-group and 33% for the combination-group. One-year overall survival rates for the ipi- and the combination-group were 54% and 55%, respectively. Conclusions: Ipilimumab should be considered as a viable treatment option for patients with failure to prior anti-PD-1 therapy, including those with progressive disease as best response to prior anti-PD-1. In contrast, the combination of ipilimumab and nivolumab appears significantly less effective in this setting compared to treatment-naïve patients.